STAmPeD: Stimulation of the Thalamus to Ameliorate Persistent Disfluency

Sponsor
University of British Columbia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05641701
Collaborator
(none)
3
1
5.9

Study Details

Study Description

Brief Summary

Persistent developmental stutter / childhood onset fluency disorder is a disabling condition leading to significant communication and psychological disability. Established treatment consists of intensive speech therapy, and whilst initially effective, has a waning long-term benefit.

Our research team aims to provide evidence of stutter management by addressing the primary neurological issue in this disorder using Deep Brain Stimulation. The investigators propose to perform bilateral DBS on 3 patients with stutter refractory to intensive speech therapy, to determine a response in their stutter. The assessments will be double-blinded. We will use the outcome of this small pilot study to determine the feasibility and details of a larger randomized controlled trial.

Condition or Disease Intervention/Treatment Phase
  • Device: System On
  • Device: System off
N/A

Detailed Description

Suitable patients are referred by speech pathology centers, after having failed an intensive speech therapy program. Referred patients are contacted by the Neurosurgery DBS Clinic, and assessed for suitability and willingness to participate.

These potential participants will be contacted by the DBS Clinic at Vancouver General Hospital to discuss the scope of the study, and educate them about deep brain stimulation. Those who wish to be included in the study will attend a face-to-face appointment at the DBS Clinic.

At the initial appointment, informed consent will take place. Baseline assessments will be undertaken, including the Overall Assessment of the Speaker's Experience of Stuttering (OASES), Voice-related Quality of Life (VRQoL), and "The One Page Stuttering Assessment". The patient will be referred for a functional MRI for mapping of speech and language laterality.

The participants will then undergo surgery for implantation of a bilateral thalamic DBS system. They will stay overnight in the hospital, and have a post-operative CT scan on the first post-operative day. This scan will be used to assess accuracy of electrode placement, as per usual technique.

4 weeks post-operatively, the participants will attend the DBS Clinic for programming of their devices.

4 weeks after device programming, the patients will attend the DBS clinic for 1-page stutter assessment with bilateral electrodes on, bilateral electrodes off, left electrode on, and right electrode on, as well as OASES and VRQoL.

The scores from the 1-page stutter assessment, as well as pre- and post-operative OASES and VRQoL, will be compared via the Wilcoxan rank sum test for nonparametric repeated measures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Each participant will act as their own control. Each individual's stutter will be assessed with DBS system OFF (control) and DBS ON (treatment).Each participant will act as their own control. Each individual's stutter will be assessed with DBS system OFF (control) and DBS ON (treatment).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Stimulation of the Thalamus to Ameliorate Persistent Disfluency: Pilot Study
Anticipated Study Start Date :
Jan 15, 2023
Anticipated Primary Completion Date :
Apr 15, 2023
Anticipated Study Completion Date :
Jul 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Deep Brain Simulation (DBS) System

The DBS device will be turned on to compare stutter to when the device was off (which would be the control).

Device: System On
The DBS system will be turned on, and the individual's stutter will be assessed.

Device: System off
The DBS system will be turned off, and the individual's stutter will be assessed.

Outcome Measures

Primary Outcome Measures

  1. Change of One-Page Suttering Assessment from Baseline to Post-Operation [Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic for 1-page stutter assessment with bilateral electrodes on.]

    Objectively assesses individual's stutter. Divide the number of instances of stuttering by the number of syllables in the sample and multiply by 100 to obtain the percentage of stuttered syllables.

Secondary Outcome Measures

  1. Change of Voice Related Quality of Life (VRQoL) from Baseline to Post-Operation [Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses quality of life post surgery.]

    A 10-question, 5 point rating scale assessment, with higher scores reflecting a worse subjective voice-related quality of life.

  2. Change of Overall Assessment of the Speaker's Experience of Stuttering (OASES) from Baseline to Post-Operation [Baseline assessment will be done pre-operatively. Four weeks after device programming, the patients will attend the DBS clinic with bilateral electrodes on to asses subjective voice experience post surgery.]

    5-point scale that indicates the amount of adverse impact a person experiences due to stuttering, with higher scores indicating higher levels of negative impact.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 76 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults between the ages of 19 and 76 years old

  • Individuals with persistent developmental stutter refractory to intensive speech therapy, as diagnosed by a speech and language therapist.

Exclusion Criteria:
  • Children and adolescents will not be included, as there is a significant percentage of developmental stuttering that will spontaneously resolve in this age group.

  • Patients who have not trialed standard therapy will not be included in this study.

  • Patients with mild symptoms.

  • Patients who have a neurodegenerative disease.

  • Patients with a bleeding diathesis.

  • Patients who are unable to communicate.

MRI Specific Exclusion criteria:
  • Patients with a cardiac pacemaker or defibrillator.

  • Patient with an insulin or infusion pump.

  • Patients with a cochlear, otologic, or ear implant.

  • Patients with an implant held in place by a magnet.

  • Patients with tissue expanders.

  • Patients with implanted clips, catheters, clamps, valves, or other metal.

  • Patients with tattoos or permanent makeup above shoulders.

  • Patients with shrapnel or other retained metal.

  • Patients who are pregnant.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of British Columbia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christopher Honey, Professor of Neurosurgery, University of British Columbia
ClinicalTrials.gov Identifier:
NCT05641701
Other Study ID Numbers:
  • H22-02984
First Posted:
Dec 8, 2022
Last Update Posted:
Dec 8, 2022
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christopher Honey, Professor of Neurosurgery, University of British Columbia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2022